OBJECTIVE: To determine the impact of ventilator-associated pneumonia (VAP) on ICU mortality, and whether it is related to time of onset of pneumonia. DESIGN: Prospective cohort study. SETTING: 16-bed medical-surgical ICU at a university-affiliated hospital. PATIENTS AND MEASUREMENTS: From 2002 to 2003, we recorded patients receiving mechanical ventilation for > 72 h. Patients developing an infection other than VAP were excluded. Patients definitively diagnosed with VAP (n=40) were cases and patients free of any infection acquired during ICU stay (n=61) were controls. The VAP-attributed mortality was defined as the difference between observed mortality and predicted mortality (SAPS II) on admission. RESULTS: Mechanical ventilation was longer in VAP patients (25 +/- 20 vs 11 +/- 9 days; p < 0.001), as was ICU stay (33 +/- 23 vs 14 +/- 12 days; p < 0.001). In the non-VAP group, no difference was found between observed and predicted mortality (27.9 vs 27.4%; p > 0.2). In the VAP group, observed mortality was 45% and predicted mortality 26.5% (p < 0.001), with attributable mortality 18.5%, and relative risk (RR) 1.7 (95% CI 1.12-23.17). No difference was observed between observed and predicted mortality in early-onset VAP (27.3 vs 25.8%; p > 0.20); in late-onset VAP, observed mortality was higher (51.7 vs 26.7%; p < 0.01) with attributable mortality of 25% and an RR 1.9 (95% CI 1.26-2.63). Empiric antibiotic treatment was appropriate in 77.5% of episodes. No differences in mortality were related to treatment appropriateness. CONCLUSIONS: In mechanically ventilated patients, VAP is associated with excess mortality, mostly restricted to late-onset VAP and despite appropriate antibiotic treatment.
OBJECTIVE: To determine the impact of ventilator-associated pneumonia (VAP) on ICU mortality, and whether it is related to time of onset of pneumonia. DESIGN: Prospective cohort study. SETTING: 16-bed medical-surgical ICU at a university-affiliated hospital. PATIENTS AND MEASUREMENTS: From 2002 to 2003, we recorded patients receiving mechanical ventilation for > 72 h. Patients developing an infection other than VAP were excluded. Patients definitively diagnosed with VAP (n=40) were cases and patients free of any infection acquired during ICU stay (n=61) were controls. The VAP-attributed mortality was defined as the difference between observed mortality and predicted mortality (SAPS II) on admission. RESULTS: Mechanical ventilation was longer in VAP patients (25 +/- 20 vs 11 +/- 9 days; p < 0.001), as was ICU stay (33 +/- 23 vs 14 +/- 12 days; p < 0.001). In the non-VAP group, no difference was found between observed and predicted mortality (27.9 vs 27.4%; p > 0.2). In the VAP group, observed mortality was 45% and predicted mortality 26.5% (p < 0.001), with attributable mortality 18.5%, and relative risk (RR) 1.7 (95% CI 1.12-23.17). No difference was observed between observed and predicted mortality in early-onset VAP (27.3 vs 25.8%; p > 0.20); in late-onset VAP, observed mortality was higher (51.7 vs 26.7%; p < 0.01) with attributable mortality of 25% and an RR 1.9 (95% CI 1.26-2.63). Empiric antibiotic treatment was appropriate in 77.5% of episodes. No differences in mortality were related to treatment appropriateness. CONCLUSIONS: In mechanically ventilated patients, VAP is associated with excess mortality, mostly restricted to late-onset VAP and despite appropriate antibiotic treatment.
Authors: J Chastre; J L Trouillet; A Vuagnat; M L Joly-Guillou; H Clavier; M C Dombret; C Gibert Journal: Am J Respir Crit Care Med Date: 1998-04 Impact factor: 21.405
Authors: Olivier Leroy; Agnès Meybeck; Thibaud d'Escrivan; Patrick Devos; Eric Kipnis; Hugues Georges Journal: Intensive Care Med Date: 2003-09-12 Impact factor: 17.440
Authors: J Vallés; A Artigas; J Rello; N Bonsoms; D Fontanals; L Blanch; R Fernández; F Baigorri; J Mestre Journal: Ann Intern Med Date: 1995-02-01 Impact factor: 25.391
Authors: A H Froon; M J Bonten; C A Gaillard; J W Greve; M A Dentener; P W de Leeuw; M Drent; E E Stobberingh; W A Buurman Journal: Am J Respir Crit Care Med Date: 1998-10 Impact factor: 21.405
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-01-31 Impact factor: 17.440
Authors: Javier Hortal; Maddalena Giannella; Maria Jesús Pérez; José Maria Barrio; Manuel Desco; Emilio Bouza; Patricia Muñoz Journal: Intensive Care Med Date: 2009-06-26 Impact factor: 17.440
Authors: Lyndsay M van de Vijsel; Sandra A N Walker; Scott E Walker; Sharon Yamashita; Andrew Simor; Michelle Hladunewich Journal: Can J Hosp Pharm Date: 2010-05
Authors: Melissa A Miller; Jennifer L Arndt; Mark A Konkle; Carol E Chenoweth; Theodore J Iwashyna; Kevin R Flaherty; Robert C Hyzy Journal: J Crit Care Date: 2010-07-23 Impact factor: 3.425